Clinical Trials Browser

ALK-positive Non-small Cell Lung Cancer × ceritinib × Clear all

NCT02513667 2023-02-03

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

Phase 2 Terminated

14 enrolled 12 charts

ALK-positive Non-small Cell Lung Cancer